Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor [abstract]

Shapiro GI, Edelman G, Calvo E, Aggarwal SK, Laird AD. Targeting aberrant PI3K pathway signaling with XL147, a potent, selective and orally bioavailable PI3K inhibitor [abstract]. Proc AACR-NCI-EORTC International Meeting on Molecular Targets and Cancer Therapeutics. 2007; A-C205.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.